The role of statins in acute coronary syndromes: Managing the unmet need

International Journal of Clinical Practice

Volumn 54, Issue 7, 2000, Pages 445-449

  Jackson, G ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; STATIN;

ANGINA PECTORIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COOPERATION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DYSPEPSIA; DYSPNEA; FATIGUE; HUMAN; ISCHEMIC HEART DISEASE; MYALGIA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT PLANNING; VERTIGO; VISUAL DISORDER;

ANTICHOLESTEREMIC AGENTS; CLINICAL PROTOCOLS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMAN; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; RECURRENCE; TREATMENT OUTCOME;

EID: 0033807731     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Management of acute myocardial infarction in intensive care units in 1995: A nationwide French survey of practice and early hospital results
2. Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group
3. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
4. The length of the hospital stay after myocardial infarction
5. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: An economic substudy of the PURSUIT trial
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
9. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
10. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
11. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes
12. The decisive importance of cholesterol lowering therapy for coronary lesions and clinical course immediately after an acute coronary event: Short and long-term results of a controlled study
13. State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: Vascular protection beyond their primary mode of action
14. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
15. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
16. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events
17. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
18. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal
19. Pharmaco-economic aspects of lipid-lowering therapy: Is it worth the price?
20. From trial data to practical knowledge: Qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia
21. Overcoming the obstacles: The outsider's view